Compare VanEck Junior Gold Miners (GDXJ) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Junior Gold Miners vs Merck & Co., Inc. — how do they compare? VanEck Junior Gold Miners trades at $114.43 (market cap $8.22B), while Merck & Co., Inc. trades at $145.6 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 42.7× VanEck Junior Gold Miners's market cap, and Merck & Co., Inc. pays a 2.39% dividend while VanEck Junior Gold Miners pays none. Which is the better fit depends on your goals — on Pluang, investors hold VanEck Junior Gold Miners for 41 Days and Merck & Co., Inc. for 98 Days on average.
| GDXJ | MRK | |
|---|---|---|
Market Cap | $8.22B | $351.28B |
Volume | 3,212,198 | 7,969,665 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $156.19 | $156.43 |
52-Week Low | $87.56 | $82.49 |
Typical Hold Time | 41 Days | 98 Days |
Enterprise Value | — | $398.04B |
Dividend Yield | — | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GDXJ, the VanEck Junior Gold Miners ETF, trades at $110.91, up 1.62% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. Recent news highlights multiple junior gold mining companies being added to the ETF, potentially increasing its diversification and appeal. Key financial ratios are not applicable as this is an ETF tracking an index of companies.
The outlook for GDXJ is influenced by gold price volatility and the performance of its underlying junior mining holdings. Opportunities exist if gold prices rise, boosting miner profitability, but risks include operational challenges and market sentiment shifts. Investors should weigh exposure to small-cap miners against broader market conditions.
Merck (MRK) trades at $142.40, down 0.28% on the day, with a bearish technical signal and key support at $140. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $2.14. Revenue grew to $65.01B in 2025, and net income reached $18.25B, though the P/E ratio is elevated at 113.9. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline.
The outlook for MRK is mixed, with solid fundamentals and analyst optimism countered by high valuation and bearish technicals. The consensus price target of $158.78 suggests upside potential, but investors face risks from competitive pressures and integration challenges from recent M&A activity. Earnings growth and pipeline developments remain key catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About VanEck Junior Gold Miners
GDXJ provides exposure to small and mid-cap companies in the global gold and silver mining industry. It focuses on 'junior' miners involved in exploration and early production, featuring 2026 leaders like Pan American Silver and Coeur Mining.
Read more on GDXJ →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
